MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

SCYNEXIS Inc

Fechado

0.83 -6.74

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.81

Máximo

0.9

Indicadores-chave

By Trading Economics

Rendimento

-1.6M

-4.4M

Vendas

317K

977K

EPS

-0.09

Margem de lucro

-453.736

Funcionários

28

EBITDA

-1.2M

-4.2M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+435.71% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.5M

38M

Abertura anterior

7.57

Fecho anterior

0.83

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

SCYNEXIS Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de abr. de 2025, 22:38 UTC

Ações em Alta

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 de abr. de 2025, 21:53 UTC

Conversa de Mercado

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 de abr. de 2025, 21:44 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 de abr. de 2025, 21:00 UTC

Principais Notícias

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 de abr. de 2025, 20:52 UTC

Conversa de Mercado

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 de abr. de 2025, 20:52 UTC

Principais Notícias

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de abr. de 2025, 20:48 UTC

Principais Notícias

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 de abr. de 2025, 20:45 UTC

Principais Notícias

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 de abr. de 2025, 20:32 UTC

Principais Notícias

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 de abr. de 2025, 20:21 UTC

Principais Notícias

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 de abr. de 2025, 20:00 UTC

Principais Notícias

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 de abr. de 2025, 19:51 UTC

Conversa de Mercado

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 de abr. de 2025, 19:37 UTC

Principais Notícias

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 de abr. de 2025, 19:32 UTC

Conversa de Mercado

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 de abr. de 2025, 19:28 UTC

Principais Notícias

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 de abr. de 2025, 19:15 UTC

Conversa de Mercado

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 de abr. de 2025, 19:12 UTC

Principais Notícias

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 de abr. de 2025, 19:11 UTC

Conversa de Mercado

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 de abr. de 2025, 19:09 UTC

Conversa de Mercado

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 de abr. de 2025, 19:09 UTC

Principais Notícias

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 de abr. de 2025, 19:00 UTC

Conversa de Mercado

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 de abr. de 2025, 18:53 UTC

Conversa de Mercado

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 de abr. de 2025, 18:51 UTC

Conversa de Mercado

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 de abr. de 2025, 18:44 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 de abr. de 2025, 18:44 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de abr. de 2025, 18:44 UTC

Conversa de Mercado

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 de abr. de 2025, 18:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 de abr. de 2025, 18:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 de abr. de 2025, 18:39 UTC

Conversa de Mercado

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Comparação entre Pares

Variação de preço

SCYNEXIS Inc Previsão

Preço-alvo

By TipRanks

435.71% parte superior

Previsão para 12 meses

Média 4.5 USD  435.71%

Máximo 5 USD

Mínimo 4 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para SCYNEXIS Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 0.9501Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.